Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Insulin Resistance & Diabetes

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Lancet
Insulin Resistance & Diabetes

Microvascular complications of obesity and diabetes-Role of bariatric surgery

Bashir B, Iqbal Z, Adam S, Ferdousi M, Chick W, Hussein HA, Syed AA, Le Roux CW, Cohen RV, Malik RA, Soran H. Microvascular complications of obesity and diabetes-Role of bariatric surgery Obes Rev
Insulin Resistance & Diabetes

Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial

Coelho C, Dobbie LJ, Crane J, Douiri A, Learoyd AE, Okolo O, Panagiotopoulos S, Pournaras DJ, Ramar S, Rubino F, Singhal R, le Roux CW, Taheri S, McGowan B. Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial Int J Obes (Lond)
Insulin Resistance & Diabetes

An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disorders

Gallagher DM, O'Harte FPM, Irwin N. An update on galanin and spexin and their potential for the treatment of type 2 diabetes and related metabolic disorders Peptides
Appetite & Satiety Insulin Resistance & Diabetes

A Complex mHealth Coaching Intervention to Prevent Overweight, Obesity, and Diabetes in High-Risk Women in Antenatal Care: Protocol for a Hybrid Type 2 Effectiveness-Implementation Study

O'Reilly SL, Laws R, Maindal HT, Teede H, Harrison C, McAuliffe FM, Geraghty A, Campoy C, Bermúdez MG, Pirhonen L, Burden C, Davies A, Laursen DH, Skinner T; IMPACT DIABETES B2B Consortium. A Complex mHealth Coaching Intervention to Prevent Overweight, Obesity, and Diabetes in High-Risk Women in Antenatal Care: Protocol for a Hybrid Type 2 Effectiveness-Implementation Study JMIR Res Protoc
Insulin Resistance & Diabetes

Daily rhythms of diabetogenic factors in men: role of type 2 diabetes and body weight

Isherwood CM, Robertson MD, Skene DJ, Johnston JD. Daily rhythms of diabetogenic factors in men: role of type 2 diabetes and body weight Endocr Connect
Insulin Resistance & Diabetes

The Effect of Synthetic Curcumin Analogues on Obesity, Diabetes and Cardiovascular Disease: A Literature Review

Lavian S, Mardaneh P, Bagherniya M, Emami SA, Butler AE, Sahebkar A. The Effect of Synthetic Curcumin Analogues on Obesity, Diabetes and Cardiovascular Disease: A Literature Review Curr Med Chem
Insulin Resistance & Diabetes

The interaction of Schistosoma mansoni infection with diabetes mellitus and obesity in mice

Amer AS, Othman AA, Dawood LM, El-Nouby KA, Gobert GN, Abou Rayia DM. The interaction of Schistosoma mansoni infection with diabetes mellitus and obesity in mice Sci Rep
Insulin Resistance & Diabetes

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Lancet
Insulin Resistance & Diabetes

Weight loss to disrupt type 2 diabetes

Alsaqaaby MS, le Roux CW. Weight loss to disrupt type 2 diabetes Diabetol Int
Insulin Resistance & Diabetes

Older posts

Page1 Page2 … Page29 Next →

Search for:

Recent Posts

ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update
ECO2023 Teaching Workshops – Registration Open!
“Addressing Obesity Together” – Press Release

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2023 ASOI